The positive results obtained with CD100 neutralization in the inflammatory mouse arthritis model, as well as the tolerability of the humanized anti-CD100 antibody suggest that anti-CD100 treatment could be explored as a therapeutic strategy for inflammatory diseases in which CD100 plays an important role, such as atherosclerosis. Here, SEMA4D is linked to arthritic joint disease.